Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery
Company Calls Off Inhaled Remdesivir Program
HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.
You may also be interested in...
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.